Calidi Biotherapeutics Director Scott Leftwich Receives Option Award

What Happened Scott Leftwich, a director of Calidi Biotherapeutics, was granted 4,000 non‑qualified stock options on August 17, 2026. The options have an exercise price of $1.36 per share (equal to the closing market price on the grant date) and were reported on a Form 4 filed August 19, 2026. The grant is recorded as a derivative acquisition (transaction code A) with no cash paid at grant.

Key Details

• Transaction date: August 17, 2026; Form 4 filed: August 19, 2026 (timely filing).
• Grant: 4,000 options; exercise price $1.36 per share (exercise cost if fully exercised = $5,440).
• Vesting: 1/12th of the options vest per month over one year commencing on the grant date (per footnote).
• Plan and policy: Granted under the issuer’s 2023 Equity Incentive Plan pursuant to the non‑employee director compensation policy.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnote notes: Footnote 1 describes the option grant and vesting schedule; Footnote 2 clarifies the count excludes previously granted options.

Context This was an option grant (award), not an exercise or sale. Because the exercise price equals the market close on the grant date, the options had no immediate intrinsic value at grant—value accrues if the stock price rises above $1.36. The monthly vesting schedule means the award vests gradually over the next year rather than all at once.